SCHEMBL6867689

SCHEMBL6867689

c1ccc2c(c1)Sc1ccccc1N2CCCCN1CCCCC1

nearest known ligand 0.74

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 16/20 0.74
▸ FPR2 P25090 2/20 0.72
▸ SIGMAR1 Q99720 1/20 0.63
▸ PIM1 P11309 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6865338 0.98 KDM1A (0.75) KDM1AFPR2SIGMAR1PIM1
SCHEMBL32690192 0.97 KDM1A (0.75) KDM1AFPR2SIGMAR1
SCHEMBL10136829 0.97 KDM1A (0.75) KDM1AFPR2SIGMAR1
SCHEMBL13305180 0.90 KDM1A (0.74) KDM1AFPR2
Pyrathiazine SCHEMBL30184095 0.88 KDM1A (0.76) KDM1A
Pyrathiazine SCHEMBL2110244 0.88 KDM1A (0.76) KDM1A
SCHEMBL10973127 0.87 KDM1A (0.84) KDM1AFPR2SIGMAR1
Pyrathiazine SCHEMBL142434 0.87 KDM1A (0.73) KDM1A
SCHEMBL20412090 0.86 KDM1A (0.85) KDM1AFPR2SIGMAR1
SCHEMBL9086478 0.86 SLC6A1 (0.63) KDM1AFPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030032801-A1 Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND 2003-02-13 — — US claimed
WO-2002089810-A1 CHEMOSENSITIZING AGENTS AGAINST CHLOROQUINE RESISTANT PLASMODIUM FALCIPARUM AND METHODS OF MAKING AND USING THEREOF UNITED STATES ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) 2002-11-14 — — WO claimed
US-6800618-B2 PHENOTHIAZINE OR IMINODIBENZYL DERIVATIVES AS ANTIMALARIAL AGENTS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY 2004-10-05 — — US disclosed
US-20030032801-A1 Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND 2003-02-13 — — US disclosed
WO-2002089810-A1 CHEMOSENSITIZING AGENTS AGAINST CHLOROQUINE RESISTANT PLASMODIUM FALCIPARUM AND METHODS OF MAKING AND USING THEREOF UNITED STATES ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) 2002-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032801-A1 Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof ABCC1, SLC11A2, G6PD KDM1A 1966/4885FPR2 90/4885SIGMAR1 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback